Clinical Trial

The Safety, Tolerability and Preliminary Efficacy of Derived Motor Neuron Progenitor Cells (XS228CN) in Subjects With Amyotrophic Lateral Sclerosis

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
A Phase I Study to Assess the Safety, Tolerability and Preliminary Efficacy of Derived Motor Neuron Progenitor Cells (XS228CN) in Subjects with Amyotrophic Lateral Sclerosis
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-08-07.
Status change: Not Yet Recruiting → Recruiting 2025-11-17
Trial Details
NCT Number NCT07118319
Lead Sponsor XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd.
Conditions Amyotrophic Lateral Sclerosis (ALS)
Enrollment 12 participants
Start Date 2025-09-15
Primary Completion 2027-01-31 (estimated)
Study Completion 2028-09-30 (estimated)
Updated on ClinicalTrials.gov 2025-11-21